We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
In the latest trading session, Pfizer (PFE - Free Report) closed at $28.61, marking a +0.7% move from the previous day. This change outpaced the S&P 500's 0.14% gain on the day. On the other hand, the Dow registered a gain of 0.3%, and the technology-centric Nasdaq increased by 0.16%.
Coming into today, shares of the drugmaker had lost 4.31% in the past month. In that same time, the Medical sector gained 4.24%, while the S&P 500 gained 4.89%.
Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to go public on January 30, 2024. The company's earnings per share (EPS) are projected to be -$0.18, reflecting a 115.79% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $14.3 billion, indicating a 41.13% decrease compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.53 per share and a revenue of $58.67 billion, signifying shifts of -76.75% and -41.53%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.94% lower within the past month. Right now, Pfizer possesses a Zacks Rank of #3 (Hold).
From a valuation perspective, Pfizer is currently exchanging hands at a Forward P/E ratio of 18.57. This expresses a premium compared to the average Forward P/E of 15.63 of its industry.
Meanwhile, PFE's PEG ratio is currently 2.65. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.65 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 54, this industry ranks in the top 22% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Pfizer (PFE - Free Report) closed at $28.61, marking a +0.7% move from the previous day. This change outpaced the S&P 500's 0.14% gain on the day. On the other hand, the Dow registered a gain of 0.3%, and the technology-centric Nasdaq increased by 0.16%.
Coming into today, shares of the drugmaker had lost 4.31% in the past month. In that same time, the Medical sector gained 4.24%, while the S&P 500 gained 4.89%.
Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to go public on January 30, 2024. The company's earnings per share (EPS) are projected to be -$0.18, reflecting a 115.79% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $14.3 billion, indicating a 41.13% decrease compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.53 per share and a revenue of $58.67 billion, signifying shifts of -76.75% and -41.53%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.94% lower within the past month. Right now, Pfizer possesses a Zacks Rank of #3 (Hold).
From a valuation perspective, Pfizer is currently exchanging hands at a Forward P/E ratio of 18.57. This expresses a premium compared to the average Forward P/E of 15.63 of its industry.
Meanwhile, PFE's PEG ratio is currently 2.65. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.65 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 54, this industry ranks in the top 22% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.